Ackman’s Pershing Square outdoes rivals

There might be a simple reason Bill Ackman’s former antagonists Dan Loeb and Carl Icahn are makin🍌g up with the iconoclastic silver-haired activist: He’s making gobs of money again.

Here’s the scoreboard, according to investors:

Ackma✨n’s Pershing Squaꦐre: up about 8 percent in April and almost 20 percent for the year.

Loeb’sꦺ Third Point༒: down 1.4 percent in April, up 1.9 percent this year.

Icahn’s Icahn Enterprises: down 1.7 🧜perc✤ent in April and 11 percent for the year.

Much of Ackmaꦦn’s stunning performance last month was due🙈 to a 34 percent gain for Allergan.

While perhaps not as contro🔴versial as Herbalife, it certainly has raised eyebrows.

Ackman spent more than $3 billion to take a 9.7 percent stake in the company and is work♏ing with Valeant to buy the drugmaker. Ackma♏n’s tactic wasn’t insider trading, he explained, because Valeant gave him the information willingly.

Loeb’s battle with Sotheby’s is not going well. The stock fell almo﷽st 4 percent in April and is down more than 20 percent for 2014.